The interaction between COMP and AT1a receptor plays a critical role in ameliorating AAA initiation and development in vivo, providing insights into an unnoticed, biased, endogenous regulatory mechanism of AT1 receptor as a modulator of vascular homeostasis and a therapeutic target for disease states. The gene discussed is AGTR1; the disease is triple-A syndrome.